Premier Path Wealth Partners LLC Increases Position in Amgen Inc. $AMGN

Premier Path Wealth Partners LLC boosted its position in Amgen Inc. (NASDAQ:AMGN) by 29.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,089 shares of the medical research company’s stock after acquiring an additional 1,388 shares during the quarter. Premier Path Wealth Partners LLC’s holdings in Amgen were worth $2,142,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Anfield Capital Management LLC raised its holdings in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its stake in Amgen by 275.0% in the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after buying an additional 55 shares in the last quarter. Board of the Pension Protection Fund purchased a new stake in Amgen in the fourth quarter worth approximately $26,000. Tower View Wealth Management LLC grew its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 63 shares during the last quarter. Finally, Manning & Napier Advisors LLC grew its position in Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the business’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.85% of the company’s stock.

Amgen Trading Up 0.4%

NASDAQ AMGN opened at $362.12 on Wednesday. The stock has a market cap of $195.44 billion, a P/E ratio of 25.20, a price-to-earnings-growth ratio of 3.62 and a beta of 0.42. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $391.29. The stock has a 50 day simple moving average of $341.06 and a two-hundred day simple moving average of $347.04. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the previous year, the firm earned $4.90 earnings per share. The business’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts forecast that Amgen Inc. will post 22.39 earnings per share for the current year.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen remains one of the most watched stocks on Zacks, and recent commentary notes the shares have had a strong multi-week and year-to-date run, suggesting continued investor interest and momentum. Article Title
• Neutral Sentiment: Viridian Therapeutics’ new FDA approval for Lumvoa is being viewed as a stronger competitor in thyroid eye disease, adding competitive pressure to Amgen’s Tepezza franchise rather than changing Amgen’s fundamentals directly. Article Title
• Negative Sentiment: The European Medicines Agency’s CHMP recommended revoking Tavneos’ marketing authorization in the EU, which raises the risk of lost international sales and creates a fresh regulatory overhang for Amgen. Article Title
• Negative Sentiment: The New England Journal of Medicine retracted the trial paper that supported Tavneos after FDA-related findings, increasing concerns about the reliability of the clinical data behind a drug that generated substantial revenue for Amgen. Article Title

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on AMGN shares. Mizuho boosted their price objective on shares of Amgen from $295.00 to $303.00 and gave the stock a “neutral” rating in a report on Tuesday, June 16th. Leerink Partners reaffirmed a “market perform” rating and set a $355.00 target price on shares of Amgen in a report on Thursday, March 5th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Jefferies Financial Group started coverage on shares of Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Finally, Piper Sandler restated an “overweight” rating on shares of Amgen in a research report on Friday, June 12th. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have given a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $354.42.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.